Page 4 - Looking Statement News Today

Transforms Approximately $3 Million in Debt Conversions into Equity PHOENIX, April 9, 2024 /PRNewswire/ -- Trutankless, Inc. , the Company recently announced the launch of its new GEN3-series of...

Trutankless, Inc. , the Company recently announced the launch of its new GEN3-series of products with design upgrades to its flagship Trutankless products. Today, the Company announces the conversion of convertible debt-to-equity by investors....

Beyond Oil Announces Details for its Annual General & Special Meeting

Merck , known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in...

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...

BASKING RIDGE, N.J. & RAHWAY, N.J., April 3, 2024 - Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been...

Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the...

Big Tree Announces $300,000 Non-Brokered Private Placement

- First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 - SOUTH PLAINFIELD, N.J., March 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. ...

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in...